Safety of Romiplostim (Nplate®) Following UCBT

Status Completed

Clinical Trial Summary

This is a single institution, phase I dose escalation study of weekly romiplostim post umbilical cord blood transplantation in patients who fail to achieve platelet engraftment by day +30. Engraftment is defined as a platelet count ≥ 20 x 109/L on 3 consecutive measurements without transfusion for 7 days. Romiplostim is administered at the assigned dose as 6 weekly injections beginning by day +42 post transplant. Up to 4 dose levels (4, 6, 8, and 10 mcg/kg/dose) will be evaluated with the maximum tolerated dose (MTD) of romiplostim determined by using the Continual Reassessment Method (CRM). The goal of this CRM will be to identify 1 of the 4 dose levels which corresponds to the desired maximum toxicity rate of 20% or less.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02046291
Study type	Interventional
Source	Masonic Cancer Center, University of Minnesota
Contact
Status	Completed
Phase	Phase 1
Start date	April 10, 2015
Completion date	June 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05433090` - An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies	N/A
Completed	`NCT00061620` - Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies	Phase 1
Enrolling by invitation	`NCT02473757` - Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Recruiting	`NCT02032446` - Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease	Phase 1/Phase 2
Recruiting	`NCT01203722` - Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies	Phase 1/Phase 2
Recruiting	`NCT02884375` - Elderly CAncer Patient	N/A
Completed	`NCT00780052` - Infusional C-myb ASODN in Advanced Hematologic Malignancies	Phase 1
Recruiting	`NCT04098393` - Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation	Phase 1
Recruiting	`NCT06028828` - Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation	Phase 2
Completed	`NCT04538599` - RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies	Phase 1
Completed	`NCT03609827` - Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Completed	`NCT01380756` - Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia	Phase 1
Recruiting	`NCT05849207` - Post-Transplant Cyclophosphamide in Patients Aged >/= 70 Years Undergoing Haploidentical Transplant	Phase 1
Not yet recruiting	`NCT05028478` - A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies	Phase 1/Phase 2
Active, not recruiting	`NCT02494258` - A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders	Phase 2
Completed	`NCT03212560` - Exercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant Patients
Active, not recruiting	`NCT02600208` - Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device	Phase 2/Phase 3
Completed	`NCT02145403` - Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies	Phase 1/Phase 2
Completed	`NCT01949545` - Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment	Phase 1
Completed	`NCT01930981` - Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life	N/A